Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3759)

Company Market Cap Price
GILD Gilead Sciences, Inc.
Oncology focus across ADCs, CAR-T, and associated pipelines supports Biotech - Oncology.
$149.39B
$120.06
-0.28%
PFE Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
$146.97B
$26.54
+2.67%
BSX Boston Scientific Corporation
Directly sells Cardiology Devices (e.g., WATCHMAN LAAC, ablation catheters, stents) and other interventional cardiology therapies.
$137.18B
$91.89
-0.74%
SYK Stryker Corporation
Orthopedic devices including implants are a core Stryker product category.
$135.37B
$353.77
-0.09%
MDT Medtronic plc
Medtronic's core cardiovascular devices include leadless pacing, ablation technologies, and related interventional products.
$128.10B
$98.52
-1.35%
WELL Welltower Inc.
Healthcare Services & Facilities – Welltower's properties function as healthcare facilities and related operations.
$124.89B
$190.66
+2.10%
VRTX Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
$115.90B
$454.48
+0.54%
HCA HCA Healthcare, Inc.
HCA operates a large network of hospitals and provides inpatient hospital services.
$113.43B
$475.47
-1.92%
BMY Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
$106.68B
$54.42
+3.84%
MCK McKesson Corporation
McKesson distributes medical devices and biometrics through its Medical-Surgical Solutions, aligning with the medical devices category.
$101.22B
$824.65
+1.33%
CVS CVS Health Corporation
CVS Health includes health benefits/insurance via Aetna, a core health insurance offering.
$100.73B
$79.78
+0.45%
WM Waste Management, Inc.
WM Healthcare Solutions provides regulated medical waste management and secure information destruction services.
$86.85B
$218.35
+1.27%
ELV Elevance Health Inc.
Direct health insurance provider (Health Insurance) – Elevance Health's core revenue comes from health benefits and risk-sharing with members.
$80.85B
$361.87
+0.78%
REGN Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
$78.57B
$754.42
+1.77%
CI Cigna Corporation
Health insurance products and related services are CI's core offering.
$73.33B
$276.46
+0.64%
MFC Manulife Financial Corporation
Disability insurance offerings as part of employee benefits/long-term protection.
$62.16B
$35.74
+0.75%
AFL Aflac Incorporated
Aflac sells health-related supplemental insurance (e.g., cancer insurance) as a core product, aligning with Health Insurance.
$58.86B
$111.51
+1.33%
BDX Becton, Dickinson and Company
BD is a global medical devices & biometrics company with multiple device-based offerings and biometric sensing capabilities.
$57.58B
$201.06
+0.08%
← Previous
1 2 3 4 ... 38
Next →
Showing page 2 of 38 (3759 total stocks)

Loading company comparison...

Loading research report...

PFE Pfizer Inc.

Pfizer and Adaptive Biotechnologies Announce Strategic Immunology Partnership to Accelerate RA Therapies

Dec 15, 2025
ELV Elevance Health Inc.

AM Best Raises Credit Ratings for Elevance Health’s Core Subsidiaries and Affirms Parent Company

Dec 13, 2025
BMY Bristol-Myers Squibb Company

FDA Grants Priority Review to Bristol‑Myers Squibb’s Opdivo‑AVD Combination for Classical Hodgkin Lymphoma

Dec 11, 2025
PFE Pfizer Inc.

Pfizer to Cut Hundreds of Jobs in Switzerland as Part of $4.5 Billion Cost‑Reduction Plan

Dec 11, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb and BioNTech Report Strong Interim Results for Pumitamig in Triple‑Negative Breast Cancer

Dec 09, 2025
PFE Pfizer Inc.

Pfizer Secures $2.1 Billion Licensing Deal with YaoPharma for Oral GLP‑1 Obesity Pill

Dec 09, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Reports Strong Early Results for Lynozyfic in Newly Diagnosed Multiple Myeloma

Dec 08, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Reports Early Success in Blood‑Cancer Bispecific Antibody Trial

Dec 06, 2025
VRTX Vertex Pharmaceuticals Incorporated

Vertex Announces First Pediatric Clinical Data for Gene Therapy CASGEVY, Expanding Age Range to 5‑11 Years

Dec 06, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Secures FDA Approval for Breyanzi in Marginal Zone Lymphoma

Dec 05, 2025
BDX Becton, Dickinson and Company

BD and ChemoGLO Partner to Expand Hazardous‑Drug Contamination Testing

Dec 04, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb to Continue ADEPT‑2 Trial for Alzheimer’s Psychosis

Dec 04, 2025
MDT Medtronic plc

Medtronic Secures FDA Clearance for Hugo RAS System in Urologic Surgery, Expanding U.S. Market Presence

Dec 04, 2025
AFL Aflac Incorporated

Aflac Partners with Ameriflex to Expand Consumer‑Directed Health Services for Public‑Sector Employers

Dec 03, 2025
BDX Becton, Dickinson and Company

BD Unveils Three‑ and Four‑Laser FACSDiscover A8 Configurations, Expanding Spectral Flow Cytometry and Imaging Access

Dec 03, 2025
MDT Medtronic plc

Medtronic Begins U.S. Commercial Launch of MiniMed 780G System Integrated with Abbott Instinct Sensor

Dec 03, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron and Tessera Announce 50/50 Gene‑Editing Partnership for Alpha‑1 Antitrypsin Deficiency

Dec 01, 2025
BMY Bristol-Myers Squibb Company

European Commission Grants Approval for Bristol‑Myers Squibb’s Breyanzi in Mantle Cell Lymphoma

Nov 25, 2025
CI Cigna Corporation

Cigna Expands Advanced Imaging Network with Empire State Radiology Agreement

Nov 25, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures EU Approval for Dupixent in Chronic Spontaneous Urticaria

Nov 25, 2025
BDX Becton, Dickinson and Company

BD Launches Surgiphor™ Surgical Wound Irrigation System in Europe with CE Approval

Nov 24, 2025
BMY Bristol-Myers Squibb Company

Texas Attorney General Files Lawsuit Against Bristol‑Myers Squibb and Sanofi Over Plavix Efficacy Claims

Nov 22, 2025
PFE Pfizer Inc.

FDA Approves PADCEV and Keytruda Combination for Muscle‑Invasive Bladder Cancer

Nov 22, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures FDA Approval for Expanded EYLEA HD Dosing, Strengthening Market Position

Nov 20, 2025
PFE Pfizer Inc.

Pfizer Settles Texas Quality‑Control Claims for $41.5 Million

Nov 19, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures EU Approval for Libtayo as First Immunotherapy in Adjuvant Treatment of High‑Risk Cutaneous Squamous Cell Carcinoma

Nov 19, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Accelerates Debt Repurchase, Settles Tender Offers Ahead of Schedule

Nov 18, 2025
HCA HCA Healthcare, Inc.

HCA HealthONE Rose Adopts Perimeter’s S‑Series OCT Imaging to Enhance Surgical Precision

Nov 18, 2025
MDT Medtronic plc

Medtronic Beats Q2 FY2026 Earnings, Raises Full‑Year Guidance on Strong Cardiac Ablation Growth

Nov 18, 2025
BDX Becton, Dickinson and Company

BD Gains WHO Prequalification for Onclarity HPV Assay, Broadening Global Cervical Cancer Screening

Nov 17, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Halts Phase 3 Milvexian Trial in Acute Coronary Syndrome

Nov 15, 2025